One eye at a time: feasibility of unilateral 0.5% pilocarpine therapy in presbyopia management
DOI:
https://doi.org/10.18203/2349-3259.ijct20262503Keywords:
Presbyopia, Pilocarpine, Miosis, Near vision, Unilateral administration, Binocular vision, Visual acuity, Pharmacological managementAbstract
Background: The objective of the study was to evaluate the feasibility, efficacy, and patient tolerance of unilateral instillation of 0.5% pilocarpine for near vision improvement in presbyopic individuals.
Methods: This prospective interventional study included 130 eyes of 65 presbyopic individuals. A single drop of 0.5% pilocarpine was instilled in one eye of each participant once daily. Distance corrected near visual acuity was assessed uniocularly and binocularly on the 7th and 15th day following initiation of treatment. Subjective improvement in near vision was recorded using patient feedback on comfort and functional near tasks. Binocular vision, stereopsis, and patient- reported outcomes regarding reading comfort, glare, headache, and overall satisfaction were documented at each visit. After completion of 15 days, the same protocol was repeated in the fellow eye of the patient, following a unilateral sequential treatment approach. Statistical analysis was performed using paired t-test and Wilcoxon signed-rank test, as appropriate.
Results: The results demonstrated a clear and progressive improvement in near visual acuity over the two-week period with unilateral administration of 0.5% pilocarpine. Subjective assessment revealed improved reading ease and reduced dependance on near correction in the majority of participants. The treatment was well tolerated. Reported ocular side effects were mild and transient, including brow ache and mild dimming of vision, with no serious adverse effects recorded.
Conclusions: Unilateral administration of 0.5% pilocarpine is an effective and safe strategy for presbyopia management, providing meaningful binocular visual function. Sequential unilateral treatment may offer a practical, patient-friendly non-surgical option for presbyopia management.
Metrics
References
Glasser A, Kaufman PL. The mechanism of accommodation in primates. Ophthalmology. 1999;106(5):863-72. DOI: https://doi.org/10.1016/S0161-6420(99)00502-3
Duane A. Normal values of accommodation. Am J Ophthalmol. 1912;49:842-50. DOI: https://doi.org/10.1001/jama.1912.04270090254042
Atchinson DA. Accommodation and presbyopia. Ophthalmic Physiol Opt. 1995;15(4):255-72. DOI: https://doi.org/10.1046/j.1475-1313.1995.9500020e.x
Glasser A, Campbell MC. Presbyopia and the optical changes in the human crystalline lens with age. Vision Res. 1998;38(2):209-29. DOI: https://doi.org/10.1016/S0042-6989(97)00102-8
Patel I, West SK. Presbyopia: prevalence, impact, and interventions. Community Eye Health. 2007;20:40-1.
Holden BA, Fricke TR, Ho SM, Wong R, Schlenther G, Cronjé S, et al. Global vision impairment due to uncorrected presbyopia. Arch Ophthalmol. 2008;126(12):1731-9. DOI: https://doi.org/10.1001/archopht.126.12.1731
Rich W, Reilly MA. A Review of Lens Biomechanical Contributions to Presbyopia. Curr Eye Res. 2023;48(2):182-194.
Knaus KR, Hipsley A, Blemker SS. A new look at an old problem: 3D modelling of accommodation reveals how age-related biomechanical changes contribute to dysfunction in presbyopia. Biomech Model Mechanobiol. 2024;23(1):193-205. DOI: https://doi.org/10.1007/s10237-023-01767-6
Ayaki M, Hanyuda A, Negishi K. Presbyopia and associated factors specific to age groups. Clin Exp Optom. 2025;12:1-6. DOI: https://doi.org/10.1080/08164622.2025.2461737
Zuo H, Cheng H, Lin M, Gao X, Xiang Y, Zhang T, et al. The effect of aging on the ciliary muscle and its potential relationship with presbyopia:a literature review. Peer J. 2024:12:e18437. DOI: https://doi.org/10.7717/peerj.18437
Cheng C. Tissue, cellular, and molecular level determinants for eye lens stiffness and elasticity. Front Ophthalmol. 2024;4:1456474. DOI: https://doi.org/10.3389/fopht.2024.1456474
Rich W, Reilly MA. A Review of Lens Biomechanical Contributions to Presbyopia. Curr Eye Res. 2023;48(2):182-94. DOI: https://doi.org/10.1080/02713683.2022.2088797
Wolffsohn JS, Davies LN. Presbyopia: Effectiveness of correction strategies. Prog Retin Eye Res. 2019;68:124-43.
Schachar RA. Cause and treatment of presbyopia with a method for increasing the amplitude of accommodation. Ann Ophthalmol. 1992;24(12):445-7.
Papadopoulos PA, Papadopoulos AP. Current management of presbyopia. Middle East Afr J Ophthalmol. 2014;21(1):10-7. DOI: https://doi.org/10.4103/0974-9233.124080
Wolffsohn JS, Davis LN. Presbyopia: Effectiveness of correction strategies. Prog Retin Eye Res. 2019;68:124-43. DOI: https://doi.org/10.1016/j.preteyeres.2018.09.004
Kohnen T, Biller ML, Lwowski C, Bohm M, Kaiser KP. Treatments for Presbyopia. Dtsch Arztebl Int. 2025;122(18):501-7. DOI: https://doi.org/10.3238/arztebl.m2025.0094
Lam D, Nagra M, Michaud L, Obinwanne CJ, Orgill M, Koschmeder J, et al. Optical interventions for presbyopia. Cochrane Database Syst Rev. 2025;6(6):CD016285. DOI: https://doi.org/10.1002/14651858.CD016285
Wolffsohn JS, Davies LN, Sheppard AL. New insights in presbyopia: impact of correction strategies. BMJ Open Ophthalmol. 2023;8:e001122. DOI: https://doi.org/10.1136/bmjophth-2022-001122
Katz JA, Karpecki PM, Dorca A, Chayet A, Koch DD, Flack AJ, et al. Presbyopia - A Review of Current Treatment Options and Emerging Therapies. Clin Ophthalmol. 2021;15:2167-78. DOI: https://doi.org/10.2147/OPTH.S259011
Haghpanah N, Alany R. Pharmacological treatment of presbyopia: A systematic review. Eur J Transl Myol. 2022;32:10781. DOI: https://doi.org/10.4081/ejtm.2022.10781
De Gracia P, Pucker AD. Pharmacological Modulation of Pupil Size in Presbyopia: Optical Modeling and Clinical Implications. J Clin Med. 2025;14:6040. DOI: https://doi.org/10.3390/jcm14176040
Grzybowski A, Kapitonovaite L, Zemaitiene R. An updated systematic review of pharmacological treatments for presbyopia. Adv Ophthalmol Pract Res. 2024;4:220-5. DOI: https://doi.org/10.1016/j.aopr.2024.09.001
Mousavi SA, Rajavi Z, Sabbaghi H, Hosseini SM, Kheiri B, Sheibani M, et al. Pharmacological Treatment of Presbyopia Using Pilocarpine 1.25% Eye Drops. J Ophthalmic Vis Res. 2024;19:468-75. DOI: https://doi.org/10.18502/jovr.v19i4.14578
Saxena R, Gupta V, Velpandian T, Sharma P, Menon V, Dada T, et al. Pilocarpine 1.25% efficacy for management of uncorrected presbyopia (PILE-UP study). Indian J Ophthalmol. 2025;73:1486-90. DOI: https://doi.org/10.4103/IJO.IJO_96_25
Singh P, Garasiya T, Ajila V, Sengupta S, Datta A, Nivean M. Efficacy and safety of pilocarpine hydrochloride ophthalmic solution USP 1.25% w/v versus placebo ophthalmic solution for the treatment of presbyopia - A multicentric clinical trial. Indian J Ophthalmol. 2025;73:1251-7. DOI: https://doi.org/10.4103/IJO.IJO_680_25
Lima GN, Amaral DC, Ivanov YA, Costa VP, Ventura CV, Moraes HV Jr, et al. Short-Term Efficacy and Safety of Pilocarpine Ophthalmic Solution for Presbyopia: A Systematic Review and Meta-Analysis. Am J Ophthalmol. 2025;280:298-307. DOI: https://doi.org/10.1016/j.ajo.2025.08.033
Waring GO 4th, Price FW Jr, Wirta D, Robinson M, Moshirfar M, Liu H, et al. Safety and Efficacy of AGN-190584 in Individuals With Presbyopia: The GEMINI 1 Phase 3 Randomized Clinical Trial. JAMA Ophthalmol. 2022;140:363-71. DOI: https://doi.org/10.1001/jamaophthalmol.2022.0059
Holland E, Karpecki P, Fingeret M, Devries D, Sharma A, Hovanesian J, et al. Efficacy and Safety of CSF-1 (0.4% Pilocarpine Hydrochloride) in Presbyopia: Pooled Results of the NEAR Phase 3 Randomized Clinical Trials. Clin Ther. 2024;46:104-13. DOI: https://doi.org/10.1016/j.clinthera.2023.12.005
Kannarr S, El-Harazi SM, Moshirfar M, Lievens CW, Lindstrom RL, Berdy GJ, et al. Safety and Efficacy of Twice-Daily Pilocarpine HCl in Presbyopia: The VIRGO Phase 3, Randomized, Double-Masked, Controlled Study. Am J Ophthalmol. 2023;253:189-200. DOI: https://doi.org/10.1016/j.ajo.2023.05.008
Waring GO 4th, Brujic M, McGee S, Liu H, Batoosingh AL, Robinson M. Impact of presbyopia treatment pilocarpine hydrochloride 1.25% on night-driving performance. Clin Exp Optom. 2024;107:665-72. DOI: https://doi.org/10.1080/08164622.2023.2279189
Renna A, Vejarano LF, De la Cruz E, Alió JL. Pharmacological treatment of presbyopia by novel binocularly instilled eye drops: a pilot study. Ophthalmol Ther. 2016;5:63-73. DOI: https://doi.org/10.1007/s40123-016-0050-x
World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191-4. DOI: https://doi.org/10.1001/jama.2013.281053
Khokhar S. Pearls on choosing presbyopia correction IOLs. Indian J Ophthalmol. 2024;72:1233-5. DOI: https://doi.org/10.4103/IJO.IJO_1643_24
Chaurasiya SK, Agarwal P. Comments on "the effect of 2% pilocarpine on depth of field in different time intervals among presbyopic subjects". Indian J Ophthalmol. 2025;73:S350-1. DOI: https://doi.org/10.4103/IJO.IJO_2913_24
Lievens CW, Hom MM, McLaurin EB, Robinson M, Liu H, Batoosingh AL, et al. Pilocarpine HCl 1.25% in post-LASIK presbyopia: pooled analysis of two phase 3 randomized trials (GEMINI 1 and 2). J Cataract Refract Surg. 2024;50:57-63. DOI: https://doi.org/10.1097/j.jcrs.0000000000001313
Abdelkader A, Kaufman HE. Clinical outcomes of combined versus separate carbachol and brimonidine drops in correcting presbyopia. Eye Vis (Lond). 2016;3:31. DOI: https://doi.org/10.1186/s40662-016-0065-3
Price FW Jr, Hom M, Moshirfar M, Berdy GJ, Lievens CW, Liu H, et al. Combinations of Pilocarpine and Oxymetazoline for the Pharmacological Treatment of Presbyopia: Two Randomized Phase 2 Studies. Ophthalmol Sci. 2021;1:100065. DOI: https://doi.org/10.1016/j.xops.2021.100065
Downloads
Published
How to Cite
Issue
Section
